Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesZevra Therapeutics Inc.

Zevra Therapeutics Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
11.59 USD 1.06 ( 10.07%)
Last update at 2026-11-06T21:00:00Z
VOLUME
1534364
Market Cap
473.53M

Momentum Score

…

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 1/2 clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
10.45
Low
11.63
High
52 Week Price Range
4.20
Low
9.76
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public disclosures on Zevra Therapeutics (NASDAQ: ZVRA) are sparse; available materials identify it as a biotechnology company developing therapeutic candidates. Its long-term growth may depend on clinical progress, regulatory approvals, partnerships and access to financing, and investors may find potential upside if development milestones are achieved.
Key risks include clinical and regulatory setbacks, high probability of financing-related dilution, and sparse public disclosure that increases uncertainty about pipeline depth and execution.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
10.53
Dividend Yield
-
Revenue TTM
40.59M
Revenue Per Share
0.82
Gross Profit TTM
32.00M
Debt / Equity
1.52
ROE
-204.78%
Net Debt
26.51M
ROCE
-17.24%
Diluted EPS TTM
-1.94

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -42.33M -8.52M -12.79M -24.54M -56.59M
Net income -41.54M -8.55M -12.76M -24.52M -56.47M
Selling general administrative 15.34M 8.70M 7.92M 10.82M 12.51M
Gross profit 10.12M 26.59M 11.98M 9.89M -
Reconciled depreciation 0.94M 0.26M 0.27M 0.30M -
Ebit -24.84M 7.73M -4.78M -20.34M -53.85M
Ebitda -24.08M 7.98M -4.69M -20.03M -53.52M
Depreciation and amortization 0.76M 0.25M 0.09M 0.31M 0.32M
Operating income -24.84M 7.73M -4.78M -20.34M -55.90M
Other operating expenses 35.30M 20.92M 18.07M 33.18M 54.27M
Interest expense 0.34M 0.38M 7.09M 6.51M 7.09M
Tax provision -0.79M 0.03M -0.03M -0.02M -
Interest income 0.76M 0.25M 0.09M 0.31M -
Net interest income 0.42M -0.13M -7.00M -6.21M -
Income tax expense -0.79M 0.03M -0.03M -0.02M -0.13M
Total revenue 10.46M 28.65M 13.29M 12.84M -
Total operating expenses 34.96M 18.86M 16.76M 30.23M 54.27M
Cost of revenue 0.34M 2.06M 1.30M 2.94M -
Total other income expense net -17.49M -16.25M -8.01M -4.21M 4.34M
Net income from continuing ops -41.54M -8.55M -12.76M -24.52M -
Net income applicable to common shares -41.54M -62.90M -12.76M -24.52M -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 178.13M 172.33M 115.53M 132.94M 11.21M
Intangible assets 68.99M 69.23M - - -
Other current assets 4.05M 26.51M 1.88M 1.18M 1.48M
Total liab 138.46M 110.46M 29.72M 5.82M 77.62M
Total stockholder equity 39.67M 61.86M 85.81M 127.12M -66.41M
Other current liab 6.14M 21.49M 2.98M 0.84M 0.17M
Common stock 0.01M 0.00M 0.00M 0.00M -
Capital stock 0.01M - 0.00M 0.00M 0.00M
Retained earnings -505.29M -399.78M -308.57M -267.03M -258.47M
Other liab - - 4.35M 0.35M 0.43M
Good will 4.70M 4.70M - - -
Other assets - - 0.72M 0.44M 0.44M
Cash 33.78M 43.05M 65.47M 112.35M 4.21M
Total current liabilities 34.06M 73.72M 11.73M 4.23M 7.54M
Current deferred revenue - - 4.66M 2.52M 5.47M
Net debt 26.51M 0.72M -51.34M -110.76M 66.14M
Short term debt 0.84M 38.24M 0.48M 0.36M 0.72M
Short long term debt - - 4.66M - 0.39M
Short long term debt total 60.30M 43.77M 14.12M 1.59M 70.35M
Other stockholder equity 544.32M 461.68M 394.26M 394.14M 192.06M
Property plant equipment - - 1.78M 2.02M 2.39M
Total current assets 86.03M 86.94M 93.02M 115.06M 8.38M
Long term investments 6.01M - 20.00M 15.42M -
Net tangible assets - - 85.81M 127.12M -66.41M
Short term investments 35.71M 24.69M 17.38M - -
Net receivables 10.51M 17.38M 8.30M 1.53M 2.58M
Long term debt 59.50M - 12.80M - 68.05M
Inventory 1.97M 9.84M - - 0.11M
Accounts payable 13.07M 13.99M 3.61M 0.52M 1.17M
Accumulated other comprehensive income 0.63M -0.04M 0.11M - -
Non currrent assets other 11.38M 9.94M 0.72M 0.44M 0.44M
Non current assets total 92.10M 85.39M 22.51M 17.89M 2.83M
Capital lease obligations 0.79M - 1.32M 1.59M 1.91M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -36.72M -15.52M -0.03M 3.23M -
Change to liabilities 3.13M -1.11M 0.93M -3.79M -
Total cashflows from investing activities -36.72M -15.52M -0.03M 3.23M -
Net borrowings 12.75M -38.10M 0.55M -0.21M -
Total cash from financing activities 8.35M 113.11M 2.74M 4.94M 28.02M
Change to operating activities 3.03M -0.29M 0.16M 0.39M -
Net income -41.54M -8.55M -12.76M -24.52M -56.47M
Change in cash -46.88M 108.02M 0.77M -15.56M 7.15M
Begin period cash flow 112.35M 4.32M 3.56M 19.12M 11.97M
End period cash flow 65.47M 112.35M 4.32M 3.56M 19.12M
Total cash from operating activities -18.72M 10.44M -1.94M -23.74M -54.20M
Issuance of capital stock 0.00M 86.04M 2.30M 0.00M -
Depreciation 0.94M 0.26M 0.27M 0.30M 0.32M
Dividends paid - -30.82M - - -
Change to inventory 0.15M 0.15M 0.15M 0.15M -
Change to account receivables -6.77M 1.05M -0.71M -1.73M -
Sale purchase of stock -4.72M -2.81M - - -
Other cashflows from financing activities 13.09M 98.80M 0.66M 5.15M -0.12M
Change to netincome 22.35M 18.94M 7.87M 3.83M -
Capital expenditures 0.09M 0.10M 0.03M 0.03M 0.02M
Change in working capital -0.47M -0.36M 0.37M -5.12M -2.29M
Stock based compensation 4.29M 2.44M 2.49M 4.41M 6.50M
Other non cash items 18.05M 0.46M 7.25M 3.19M 3.71M
Free cash flow -18.81M 10.34M -1.97M -23.76M -54.22M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ZVRA
Zevra Therapeutics Inc.		 1.06
10.07%		 11.59 - 10.70 11.67 11.54 11.65 -4.24
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Zevra Therapeutics Inc.

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 1/2 clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

1180 Celebration Boulevard, Celebration, FL, United States, 34747

321 939 3416

https://zevra.com

59

Name Title Year Born
Mr. Neil F. McFarlane President, CEO & Director 1973
Ms. Christal M. M. Mickle M.A. Co-Founder & Chief Development Officer 1979
Mr. R. LaDuane Clifton CPA CFO, Secretary & Treasurer 1972
Mr. Joshua M. Schafer M.B.A. Chief Commercial Officer & Executive VP of Business Development 1972
Dr. Sven Guenther Ph.D. Chief Scientific Officer 1972
Ms. Nichol L. Ochsner Vice President of Investor Relations & Corporate Communications NA
Dr. Christopher M. Lauderback Ph.D. Senior Vice President of Manufacturing 1975
Dr. Rene A. Braeckman Ph.D. Senior Vice President of Clinical Development NA
Dr. Daniel Gallo Ph.D. Senior Vice President of Medical Affairs & Advocacy NA
Dr. Adrian Quartel FFPM, M.D. Chief Medical Officer 1961

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…